Overview

Treatment Response of High-dose and Standard-dose Rabeprazole for Extra-esophageal Reflux.

Status:
Completed
Trial end date:
2014-05-21
Target enrollment:
0
Participant gender:
All
Summary
This is a single-center, randomized, open-label clinical study to assess the treatment response of high-dose rabeprazole compared with standard-dose rabeprazole in patients with extra-esophageal manifestations of gastroesophageal reflux disease.
Phase:
Phase 3
Accepts Healthy Volunteers?
No
Details
Lead Sponsor:
Seoul National University Hospital
Collaborator:
IlDong Pharmaceutical Co Ltd
Treatments:
Rabeprazole
Criteria
Inclusion Criteria:

- Age is over 20 years old, under 80 years old, men or women

- Patients who had experienced extra-esophageal symptoms of gastroesophageal reflux
disease more than once a week within the last month prior to the start of the study

Exclusion Criteria:

- Patients administered with prokinetics, H2 receptor antagonists, proton pump
inhibitors, anticholinergic drugs or non-steroid anti-inflammatory drugs prior to
study in 4 weeks

- Patients administered with anti-thrombotic drugs

- Patients taking other investigational drugs or participating in other clinical studies
in 4 weeks

- Patients with esophageal stricture, esophageal varix, Barrett's esophagus, peptic
ulcer or gastrointestinal bleeding

- Patients with Zollinger-Ellison syndrome

- Patients with any kind of malignant tumor

- Patients with surgery related to gastroesophageal

- Patients with significant cardiovascular, pulmonary, heptic, renal, hemopoietic or
endocrine system primary disease

- Patients with neuropsychiatric disorder, alcoholism, or drug abuse

- Women either pregnant or breast feeding